Lysoway Therapeutics has developed unique technological approaches to screen and develop potent modulators of lysosomal ion channels, including TRPML1 and TMEM175. These small-molecule compounds can restore autophagic flux and resolution, as well as enhance plasma membrane repair through direct activation of lysosomal exocytosis. These modulators have great potential to treat neurodegenerative diseases with genetic defects in lysosomal function or rare diseases characterized by toxic accumulation of cellular wastes.

Life Sciences

Medical Devices

Therapeutics

Lysoway Therapeutics

Lysoway Therapeutics' headquarters in Cambridge, MA, United States

Description

People (1)

Jobs (0)

Other offices